About Vaccicure         Product         News          Contact

About Vaccicure

7th July 2015 marks the launch of the Vaccicure investment opportunity. Vaccicure Limited, the company set up to fund the clinical trials of the Polyclonal Antibody Stimulator (PAS) developed by Cancer Advances Inc., has now produced the final Information Memorandum that will be made available to qualifying investors from 7th July. Funding is through the purchase of Redeemable Preference Shares. The opportunity is only available to high net worth investors, sophisticated investors and investment professionals. For more information about investing contact the Keyholder Funding Team.


Visit Cancer Advances Website Click Here to Visit Cancer Advances Inc. Website



Executive Directors



Allen Cato, M.D., Ph.D.

 

Allen Cato, M.D., Ph.D.As a cofounder of Cancer Advances, Dr. Cato created and maintains the corporate vision. In addition, he directs sponsor interactions, and seeks business opportunities and strategic alliances with other companies and organizations. Dr. Cato serves as an advisor on project teams and develops complex strategic development plans and study designs. He maintains hands-on experience with all phases of the development process, and is especially skillful in devising regulatory and clinical strategies and representing sponsors at regulatory meetings.

Dr. Cato cofounded Cato Research and Cato BioVentures and has more than 45 years of experience in clinical study design, regulatory interactions, adverse drug reactions, and clinical research and new drug development. He has directed or participated in the development of more than 100 INDs and NDAs. Dr. Cato has published more than 100 papers, principally in the field of clinical pharmaceutical research, and he participates as a member of the board of directors for several pharmaceutical and biotechnology companies.


Lynda Sutton, B.Sc.

 

Lynda Sutton, B.Sc.Ms. Sutton has more than 25 years of experience in the drug development industry, specializing in the development of regulatory strategies for drugs and biologics. She has coordinated activities in various disciplines (e.g., toxicology, pharmacology, pharmacokinetics, analytical and pharmaceutical development, and clinical research). Ms. Sutton has been involved in the development of new clinical entities; has overseen the preparation of FDA pre-meeting submissions; and has ensured that regulatory requirements necessary for the approval and launch of new products have been satisfied.

Since cofounding Cato Research in 1988, Ms. Sutton has served as project leader or project advisor on numerous project teams. In this capacity, she has been responsible for the strategic planning of full development programs for both drugs and biologics in a variety of therapeutic areas. In her current position, Ms. Sutton provides interpretation, guidance, and advice on regulatory issues; oversees the preparation of regulatory submissions; reviews documents that will be submitted to regulatory agencies; initiates and facilitates FDA interactions on behalf of sponsors; and assists with the development of regulatory strategies. She has served as the primary regulatory contact for more than 100 sponsors over the last 10 years. As the primary regulatory contact at Cato Research, she develops and coordinates strategies for regulatory agency meetings, and serves as the moderator at these meetings.

In addition, Ms. Sutton has cofounded several small biotechnology companies and serves as a member of the board of directors for several companies. She has expertise in the development of biological products, with emphasis on gene therapy and blood products, and in the development of oncological, anti-infective, and neuropharmacological products.


John Wingen

 

John Wingen, Mr. Wingen is the Chief Financial Officer of Cato Research LTD. He will be the Finance Director of the Company.



 

 

Non-Executive Directors


Laurence Cohen

Larry CohenMr. Cohen is an English Solicitor. He was in private practice for over 40 years, including 19 years at a specialist Intellectual Property firm, Bristows, (10 years as a partner), and for 7 years until his retirement in December 2014, as a partner of Latham & Watkins LLP. Mr Cohen initially specialised in Intellectual Property Litigation, including a number of cases for the pharmaceutical and medical device industries. Latterly he assisted IP rich companies structure efficiently. He has been involved in a number of IP based cross border due diligences in relation to mergers and acquisitions. He has advised on certain aspect of pharmaceutical medical device regulatory law in the EU, and been involved in leading matters relating to the interface of IP and anti-trust law in Europe. In 2010 he led a team advising the government of Abu Dhabi relation on the modernising of their IP laws and environment to meet the challenges of moving from an oil based economy to a tech based economy under the 2030 plan. Mr Cohen is also a director of DiaTech Oncology Limited and DiaTech Oncology TPA Limited.



Dr. Arthur Fowle FRCP

Dr. Fowle trained at King's College Hospital, London, intending to practise cardiology. He joined Wellcome Research Laboratories, Beckenham, in 1965 as a clinical physiologist. Security of tenure was promised if he became a part-time consultant physician in the NHS. In the interval, clinical pharmacology was formally recognized as the discipline which he practised. He became head of the clinical pharmacology department in 1968 and part-time consultant general physician in the same year. He retired from Wellcome in 1992. Dr Fowle is an expert in the conduct of clinical trials.



Lee McCracken, M.Sc., MBA

Lee McCracken, M.Sc., MBALee McCracken is Chairman of Global Medical and Research Technologies since May 2016 following his appointment as a Director in 2015. Global Medical is developing novel solutions for Organ Transplantation, Immuno-Oncology, and Regenerative Medicine. Previously, he was CEO of Gensignia Life Sciences, a miRNA-digital information technology company focused on proprietary blood-based tests for the early detection of lung cancer, from 2014 to 2016. Mr. McCracken is an executive leader whose background spans start-ups to commercial organizations with significant revenues. In addition he has substantial transactions experience in the diagnostic and pharmaceutical sectors, plus venture capital experience.

Mr. McCracken has also served as President & CEO of Pathwork Diagnostics, a venture capital backed company that developed and commercialized an FDA-cleared diagnostic for difficult to diagnose cancers, which was acquired by Response Genetics in 2013. Previously, he served as Corporate Head of Business Development at Prometheus Laboratories, a leading personalized medicine company with diagnostic and pharmaceutical products in gastroenterology and oncology, which grew to over $500 million in sales prior to Registered Office: 9th Floor, The Royal Liver Building, Pier Head, Liverpool. L3 1JH Registered in England & Wales No. 08988870 its acquisition by Nestle Health Science in 2011.

Earlier, Mr. McCracken was SVP Pharmaceutical Business Development of Diversa Corporation a genomic technology company which was merged into Verenium, President & CBO of GenStar Therapeutics, a pre-clinical gene therapy company which merged into Corautus, SVP Corporate Development at CombiChem, a venture capital backed company acquired by DuPont Pharmaceuticals, and Director Business Development / Managing Director at Allergan / Pacific Pharma. Mr. McCracken also held positions in the venture capital industry with Union Venture and 3i Capital (a US subsidiary of 3i Group plc). Mr. McCracken received a B.S. from Santa Clara University, an M.Sc. in Computer Science from the University of Dayton and an M.B.A. from Anderson School of Management at UCLA.



Warren Stern PhD

Dr Stern is the owner of Stern Drug Development, LLC and has more than 30 years of pharmaceutical product development experience in a wide variety of therapeutic areas and drug delivery systems, including preclinical (pharmacology, ADME, formulation development, toxicology) and clinical research in early stage companies. This includes pre-IND to IND filings for pharma and contract research organizations, first in man clinical trials, coordination of complex multicenter phase II-III clinical studies and IND/NDA/sNDA submissions. Areas of expertise include preclinical and clinical testing of drugs for sickle cell disease, analgesic drugs, psychiatric and neurological disorders, hypoxia and SpO2 measures, asthma, obesity, bone metabolism, stroke and other therapeutic areas, oral and parenteral drug delivery systems, regulatory considerations, intellectual property strategy, commercial relationships with pharmaceutical companies and government agencies. Holds more than 10 issued and pending pharmaceutical use-patents, including applications related to: a method of determining risk of experiencing a hypoxic episode in subjects receiving opioid medications; and for a method of enhancing the action of 5-HMF in improving blood oxygenation.

Entrepreneurial experience includes CEO/President position at a publicly held early stage drug delivery company (Pharmatec), co-founding of Research Triangle Pharmaceuticals (a subsidiary of Cato Holdings; acquired by SkyePharma) and co-founding of Nobex Corp. (acquired by Biocon). He was also the SVP of Drug Development and an investor in AesRx LLC (acquired by Baxter). Major pharma experience for 12 years included Head of Clinical Neuroscience at Burroughs Wellcome Company and Senior Vice President of Clinical Research at Forest Laboratories.

In respect to education, Dr Stern received a B.S. from City University of New York (Brooklyn College) in 1965, a PhD from Indiana University, Ph.D., in Psychopharmacology in 1969, and held Post-Doctoral Fellowships in Neurophysiology--Boston State Hospital 1970-1971 and Neuropharmacology--Worcester Foundation for Experimental Biology, 1971-1972.




Product

Polyclonal Antibody Stimulator (PAS) is a fusion peptide being developed for the treatment of gastrointestinal cancers, metastatic gastrinoma, and colorectal adenoma.

Few products are currently in late-stage clinical development for the treatment of gastric and pancreatic cancer. Because there remains a significant unmet medical need, a wide variety of immunomodulators are being developed including cytokines, adaptive T-cells, therapeutic vaccines, and monoclonal antibodies; PAS falls under the broad category of therapeutics known as immunomodulators. PAS functions by stimulating the immune system in the recipient to produce endogenous polyclonal antibodies to gastrin without the risks and limitations associated with serum-derived polyclonal treatment or monoclonal antibody therapy.

Contact


Email VaccicureSend Us An Email    Call VaccicureCall Us: +1-919-361-2286
Vaccicure Limited
Floor 9, The Royal Liver Building
Pier Head
Liverpool L3 1JH
England